MKI67 and neoplasm: Analysis of serial sections showed that 77.3 ± 7.9% and 74.64 ± 12.3% of tumoral CEP-DilC18s were localized to the actively growing peritumoral region 3 and 13 days after administration, respectively, shown representatively in Figure 3B, in the vicinity of peritumoral Ki-67+ proliferating tumor cells (Fig. 3C).